Literature DB >> 21813063

A novel ex vivo organotypic culture model of alkaptonuria-ochronosis.

L Tinti1, A Spreafico, F Chellini, M Galeazzi, A Santucci.   

Abstract

OBJECTIVES: Alkaptonuria (AKU) is an orphan disease that has an estimated prevalence of 0.3/100,000. The disease is caused by the lack of activity of homogentisic acid oxidase (HGO), an enzyme involved in tyrosine and phenylalanine metabolism. To date, there is only one drug, the nitisinone, with orphan designation authorised by both Food and Drug Administration (FDA) and European Medical Agency (EMA) for AKU. A clinical trial on AKU patients using nitisinone has recently been completed but it needs further investigation for long-term therapy. In recent years our group has developed a series of AKU in vitro models using cell lines, primary chondrocytes and human plasma in order to test the efficacy of new substances, mainly antioxidant compounds, for AKU therapy. Herein, we report the optimisation of an ex vivo reproducible culture method exploiting cartilage slices in order to investigate the deposition of ochronotic pigment in this kind of connective tissue.
METHODS: Human normal cartilage slices, obtained after surgery for prosthesis replacement, were cultured for several days in the presence of a sublethal concentration of homogentisic acid (HGA).
RESULTS: After two months of incubation with HGA, the peculiar melanin-like ochronotic pigmentation can be observed into the cartilage tissue.
CONCLUSIONS: This novel organo-typic ex vivo model could be extremely useful to investigate the efficacy of substances able to ameliorate the conditions of AKU patients. Moreover, it could be used for genetic and proteomic investigations to better define AKU pathophysiology.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21813063

Source DB:  PubMed          Journal:  Clin Exp Rheumatol        ISSN: 0392-856X            Impact factor:   4.473


  10 in total

Review 1.  Amyloidosis in alkaptonuria.

Authors:  Lia Millucci; Daniela Braconi; Giulia Bernardini; Pietro Lupetti; Josef Rovensky; Lakshminaryan Ranganath; Annalisa Santucci
Journal:  J Inherit Metab Dis       Date:  2015-04-14       Impact factor: 4.982

2.  Homogentisate 1,2 dioxygenase is expressed in human osteoarticular cells: implications in alkaptonuria.

Authors:  Marcella Laschi; Laura Tinti; Daniela Braconi; Lia Millucci; Lorenzo Ghezzi; Loredana Amato; Enrico Selvi; Adriano Spreafico; Giulia Bernardini; Annalisa Santucci
Journal:  J Cell Physiol       Date:  2012-09       Impact factor: 6.384

3.  Biochemical and proteomic characterization of alkaptonuric chondrocytes.

Authors:  Daniela Braconi; Giulia Bernardini; Claretta Bianchini; Marcella Laschi; Lia Millucci; Loredana Amato; Laura Tinti; Tommaso Serchi; Federico Chellini; Adriano Spreafico; Annalisa Santucci
Journal:  J Cell Physiol       Date:  2012-09       Impact factor: 6.384

4.  Diagnosis of secondary amyloidosis in alkaptonuria.

Authors:  Lia Millucci; Lorenzo Ghezzi; Giulia Bernardini; Daniela Braconi; Pietro Lupetti; Federico Perfetto; Maurizio Orlandini; Annalisa Santucci
Journal:  Diagn Pathol       Date:  2014-09-26       Impact factor: 2.644

5.  Chondroptosis in alkaptonuric cartilage.

Authors:  Lia Millucci; Giovanna Giorgetti; Cecilia Viti; Lorenzo Ghezzi; Silvia Gambassi; Daniela Braconi; Barbara Marzocchi; Alessandro Paffetti; Pietro Lupetti; Giulia Bernardini; Maurizio Orlandini; Annalisa Santucci
Journal:  J Cell Physiol       Date:  2015-05       Impact factor: 6.384

Review 6.  Melanins as Sustainable Resources for Advanced Biotechnological Applications.

Authors:  Hanaa A Galeb; Emma L Wilkinson; Alison F Stowell; Hungyen Lin; Samuel T Murphy; Pierre L Martin-Hirsch; Richard L Mort; Adam M Taylor; John G Hardy
Journal:  Glob Chall       Date:  2020-11-25

7.  A molecular spectroscopy approach for the investigation of early phase ochronotic pigment development in Alkaptonuria.

Authors:  Andrea Bernini; Elena Petricci; Andrea Atrei; Maria Camilla Baratto; Fabrizio Manetti; Annalisa Santucci
Journal:  Sci Rep       Date:  2021-11-19       Impact factor: 4.379

8.  Homogentisate 1,2 dioxygenase is expressed in brain: implications in alkaptonuria.

Authors:  Giulia Bernardini; Marcella Laschi; Michela Geminiani; Daniela Braconi; Elisa Vannuccini; Pietro Lupetti; Fabrizio Manetti; Lia Millucci; Annalisa Santucci
Journal:  J Inherit Metab Dis       Date:  2015-03-12       Impact factor: 4.982

9.  Alkaptonuria is a novel human secondary amyloidogenic disease.

Authors:  Lia Millucci; Adriano Spreafico; Laura Tinti; Daniela Braconi; Lorenzo Ghezzi; Eugenio Paccagnini; Giulia Bernardini; Loredana Amato; Marcella Laschi; Enrico Selvi; Mauro Galeazzi; Alessandro Mannoni; Maurizio Benucci; Pietro Lupetti; Federico Chellini; Maurizio Orlandini; Annalisa Santucci
Journal:  Biochim Biophys Acta       Date:  2012-07-28

10.  Antioxidants inhibit SAA formation and pro-inflammatory cytokine release in a human cell model of alkaptonuria.

Authors:  Adriano Spreafico; Lia Millucci; Lorenzo Ghezzi; Michela Geminiani; Daniela Braconi; Loredana Amato; Federico Chellini; Bruno Frediani; Elena Moretti; Giulia Collodel; Giulia Bernardini; Annalisa Santucci
Journal:  Rheumatology (Oxford)       Date:  2013-05-23       Impact factor: 7.580

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.